OP0152 Effects of Tofacitinib Monotherapy versus Methotrexate on Patient-Reported Outcomes in the 2-Year Phase 3 Oral Start TRIAL in Methotrexate-NaÏVe Patients with Rheumatoid Arthritis
Authors: R. Alten, V. Strand, R. Fleischmann, T. Koncz, S. Zwillich, J. Bradley, D. Gruben, B. Wilkinson, S. Krishnaswami, G. Wallenstein
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Tofacitinib is a novel, oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). <h3>Objectives</h3> To compare the effects of twice daily (BID) tofacitinib 5 mg and 10 mg monotherapy versus methotrexate (MTX) on patient-reported outcomes (PROs) in the 24-month Phase 3, randomised, double-blind, parallel-group ORAL Start study (NCT01039688) in MTX-naïve patients. Results from a 12-month interim analysis have been presented previously [1,2] here we present the final analysis at 24 months. <h3>Methods</h3> MTX-naïve patients with moderate-to-severe active RA were randomised 2:2:1 to receive tofacitinib 5 mg (n=373) or 10 mg BID (n=397), or MTX (n=186) titrated from 10 mg per week to 20 mg per week by Week 8. Secondary PRO endpoints included the mean change from baseline in: Patient Global Assessment of arthritis (PtGA; Visual Analogue Scale [VAS]), pain (VAS), physical function (Health Assessment Questionnaire-Disability Index; HAQ-DI), fatigue (Functional Assessment of Chronic Illness Therapy-Fatigue Scale; FACIT-F), and health-related quality of life (HR-QoL; Short Form 36 version 2, acute; SF-36). Analyses used a linear mixed-effect model with baseline values as covariates in the full analysis set (all randomised patients who received ≥1 dose of study drug and had ≥1 post-baseline measurement). Least squares (LS) mean changes from baseline (±standard error [SE]) and proportions of patients reporting improvements ≥minimum clinically important differences (MCID; no imputation for missing data) in PROs at Month 24 are presented. P-values presented here are with no correction for type I error inflation. <h3>Results</h3> A total of 658 patients completed the 24-month study (266, 286, and 106 in the tofacitinib 10 mg and 5 mg and MTX groups, respectively). Over 24 months, significantly (p&lt;0.05) greater improvements from baseline were observed with both tofacitinib 5 and 10 mg BID compared with MTX across the PROs analysed, with the exception of the SF-36 mental component summary score, which was significant at Month 3 but not later (Table 1). Compared with MTX, significantly greater proportions of patients receiving tofacitinib 10 mg BID reported changes ≥MCID in all PROs at Month 3, and all PROs, except HAQ-DI, at Months 12 and 24 and FACIT-F at Month 12. Numerically more patients administered tofacitinib 5 mg BID reported changes ≥MCID across PROs versus MTX. <h3>Conclusions</h3> In this Phase 3 trial in MTX-naïve patients with RA, tofacitinib 5 and 10 mg BID monotherapy significantly improved multiple PROs over 24 months compared with MTX. <h3>References</h3> Lee EB et al. Arthritis Rheum 2012; 64 (Suppl 10): S1049. Strand V et al. Ann Rheum Dis 2013; 72: 252-253. <h3>Acknowledgements</h3> Writing support was provided by Erin Bekes PhD, of Complete Medical Communications and funded by Pfizer Inc. <h3>Disclosure of Interest</h3> R. Alten Grant/research support: Pfizer Inc, Speakers bureau: Pfizer Inc, V. Strand Consultant for: Pfizer Inc, R. Fleischmann Grant/research support: Pfizer Inc, Consultant for: Pfizer Inc, T. Koncz Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, S. Zwillich Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, J. Bradley Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, D. Gruben Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, B. Wilkinson Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, S. Krishnaswami Shareholder of: Pfizer Inc, Employee of: Pfizer Inc, G. Wallenstein Shareholder of: Pfizer Inc, Employee of: Pfizer Inc <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3168